Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner, Darrell J. White, Lionel Karlin, Lotfi Benboubker, Sophie Rigaudeau, Philippe Rodon, Eric Voog, Sung Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Philip Twumasi-Ankrah, Godwin Yung, Robert M. Rifkin, Philippe Moreau, Sagar Lonial, Shaji K. KumarPaul G. Richardson, S. Vincent Rajkumar

Research output: Contribution to journalArticlepeer-review

63 Citations (Scopus)
Original languageEnglish
Pages (from-to)3616-3628
Number of pages13
JournalBlood
Volume137
Issue number26
DOIs
Publication statusPublished - Jul 1 2021
Externally publishedYes

ASJC Scopus Subject Areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma'. Together they form a unique fingerprint.

Cite this